(S1 (S (NP (NP (JJ Medical) (NN therapy)) (PP (IN for) (NP (NN intermittent) (NN claudication))) (. .))))
(S1 (S (S (NP (NP (JJ Medical) (NN therapy)) (VP (TO to) (VP (VP (VB improve) (NP (NNS symptoms))) (, ,) (VP (VB stabilise) (NP (DT the) (JJ underlying) (JJ vascular) (NN disease))) (CC and) (VP (VB improve) (NP (ADJP (RBR lower) (JJ limb)) (NNS outcomes)))))) (VP (VBZ is) (NP (NP (DT an) (ADJP (ADJP (JJ important)) (CC and) (ADJP (JJ effective))) (NN adjunct)) (PP (TO to) (NP (NP (NP (JJ lifestyle) (NN modification)) (CC and) (NP (ADJP (ADJP (JJ surgical)) (CC or) (ADJP (JJ endovascular))) (NNS interventions))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN IC)))))))))) (. .)))
(S1 (S (S (NP (JJ Randomised) (NN placebo) (JJ controlled) (NNS trials)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (DT the) (NN phosphodiesterase) (CD III) (NN inhibitor) (NN cilostazol) (NN 100mg) (NN bid)) (VP (VBZ improves) (NP (NP (JJ pain-free) (CC and) (JJ maximum) (JJ walking) (NN distance)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))) (, ,) (PP (IN in) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ intermittent) (NN claudication)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN tissue) (NN necrosis)) (CC or) (NP (NN rest) (NN pain)))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN review)) (VP (VBZ summarises) (NP (NP (DT the) (NN evidence)) (PP (IN from) (NP (NP (CD 8) (JJ pivotal) (NNS trials)) (PP (IN of) (NP (NN cilostazol))) (VP (VBG involving) (PP (IN over) (NP (NP (CD 2000) (NNS patients)) (PP (IN with) (NP (NN intermittent) (NN claudication))) (VP (VBN treated) (PP (IN for) (NP (QP (RB up) (TO to) (CD 6)) (NNS months)))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (ADJP (RB comparatively) (JJR less)) (NN evidence)) (S (VP (TO to) (VP (VB support) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ other) (NN treatment) (NNS modalities))) (PP (IN for) (NP (NP (NN relief)) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN in) (NP (NN intermittent) (NN claudication)))))))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ considerable) (NN interest)) (PP (IN in) (NP (JJ therapeutic) (NN angiogenesis))) (S (VP (TO to) (VP (VP (VB promote) (NP (JJ new) (NN vessel) (NN formation))) (CC and) (VP (VB enhance) (NP (NP (NN collateralisation)) (PP (IN of) (NP (NP (DT the) (JJR lower) (NN limb)) (VP (VBG using) (NP (NP (JJ recombinant) (NN growth) (NN factor) (NNS proteins)) (CC or) (NP (NN gene) (NN transfer) (NNS strategies)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN rationale)) (PP (IN for) (NP (JJ therapeutic) (NN angiogenesis)))) (VP (VBZ is) (VP (VBN discussed) (, ,) (ADVP (RB together)) (PP (IN with) (NP (NP (DT the) (ADJP (RBS most) (JJ recent)) (NNS results)) (PP (IN from) (NP (NP (JJ randomised) (NNS trials)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ peripheral) (JJ arterial) (NN disease)))))))))))) (. .)))
